Clinical Trials Arena on MSN
FDA finalises psychedelic clinical trial guidance
The FDA is holding a public hearing to talk through psychedelic drug development on 14 September.
The head of the Food and Drug Administration said the agency will soon unveil a new framework detailing what companies must do to seek approval of vaccines, a move that comes as the Trump ...
12d
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive ...
FDA’s recently unveiled 2025 Human Foods Program guidance agenda offers a detailed view of the agency’s priorities for the year ahead. The document is non-binding, but provides critical insight ...
A new guidance document issued by the FDA this week offers recommendations for how makers of prescription biosimilars and biologic reference products should approach promotional advertising and ...
The FDA's draft guidance could streamline biosimilar approval by reducing the need for comparative efficacy studies, emphasizing analytical assessments instead. This approach may lower development ...
The US Food and Drug Administration (FDA) has released a draft guidance detailing how manufacturers should address Form 483 observations following a drug good manufacturing practice (GMP) ...
Marty Makary resigned as FDA commissioner amid controversy. But his reforms to drug review times and AI are the agency's ...
You can’t call it cheatin’, she reminds me of you,” the Gin Blossoms sang on their 1996 album Congratulations I’m Sorry. For sponsors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results